睿知中国医院研究地图
候选清单

正在招募淋巴瘤I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Exploration of Circular RNA in B-cell Hematologic Malignancies

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由上海交通大学医学院附属瑞金医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方上海交通大学医学院附属瑞金医院Ruijin Hospital上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07774572,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 7

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(7 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. ECOG performance status 0 or 1.and have archival tumor biopsy tissue and pathology report from the most recent relapse, or at least one palpable superficial tumor lesion at screening, and agree to biopsy/resection before the first dose of IP for disease confirmation.

    入选标准第 10 条

  3. Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable).

    入选标准第 11 条

    For patients with prior CD19-targeted therapy, confirmed CD19 positivity at screening.

    入选标准第 14 条

    Women of childbearing potential (WOCBP) must have a negative serum pregnancy test and agree to use effective contraception during the study and for 6 months after last treatment.

    入选标准第 15 条

    Male patients with female partners must agree to use condoms, and partners must use effective contraception, during the study and for 6 months after last treatment.

    入选标准第 16 条

    Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).

    排除标准第 1 条

    Received prohibited treatments within 4 weeks before dosing, including high-dose corticosteroids (>20 mg prednisone equivalent daily), chemotherapy, immunosuppressive therapy, prior CAR-T or other gene/cell therapy, or T-cell engagers.

    排除标准第 16 条

    Participation in another clinical study with investigational therapy within 3 months before dosing, or prior participation in cell/gene therapy trials.

    排除标准第 17 条

  4. Inadequate hematologic function (ANC <1.0×10⁹/L, Hb <70 g/L, PLT <50×10⁹/L, lymphocytes ≤0.5×10⁹/L) or coagulation abnormalities (INR/APTT ≥1.5×ULN).

    排除标准第 10 条

    Hepatic impairment (ALT/AST >2×ULN, or >3×ULN with hepatic involvement; bilirubin >2×ULN, unless Gilbert syndrome).

    排除标准第 11 条

  5. Measurable disease per Lugano 2014 or iwCLL 2018 criteria.

    入选标准第 12 条

    Planned radiotherapy within 6 weeks after screening (unless only non-irradiated PET-positive lesions remain eligible).

    排除标准第 18 条

  6. History of another primary malignancy within the past 3 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.

    排除标准第 5 条

    Active hepatitis B (HBsAg-positive with detectable HBV DNA) or hepatitis C (HCV RNA-positive) infection.

    排除标准第 6 条

    Active or prior HIV infection.

    排除标准第 7 条

  7. Pregnancy or breastfeeding.

    排除标准第 15 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);日常活动能力。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07774572,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age ≥ 18 years, any gender.
  2. Able to provide written informed consent.
  3. Confirmed diagnosis of relapsed/refractory (R/R) CD19-positive B-cell malignancy, including:
  4. Diffuse large B-cell lymphoma (DLBCL)
  5. Follicular lymphoma (FL)
  6. Mantle cell lymphoma (MCL)
  7. Small lymphocytic lymphoma (SLL)/chronic lymphocytic leukemia (CLL)
  8. Waldenström macroglobulinemia (WM)
  9. Marginal zone lymphoma (MZL)
  10. ECOG performance status 0 or 1.and have archival tumor biopsy tissue and pathology report from the most recent relapse, or at least one palpable superficial tumor lesion at screening, and agree to biopsy/resection before the first dose of IP for disease confirmation.
  11. Disease refractory to or relapsed after ≥ 2 prior lines of standard therapy, including required agents per disease subtype (e.g., anti-CD20, BTK inhibitors, chemotherapy, or ASCT if applicable).
  12. Measurable disease per Lugano 2014 or iwCLL 2018 criteria.
  13. LVEF ≥ 40% by echocardiogram.
  14. For patients with prior CD19-targeted therapy, confirmed CD19 positivity at screening.
  15. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test and agree to use effective contraception during the study and for 6 months after last treatment.
  16. Male patients with female partners must agree to use condoms, and partners must use effective contraception, during the study and for 6 months after last treatment.

排除标准:Exclusion Criteria:

  1. Prior anticancer therapy-related toxicities unresolved to baseline or ≤ Grade 1 (alopecia and peripheral neuropathy excepted).
  2. Central nervous system (CNS) involvement by lymphoma.
  3. Need for urgent treatment due to tumor mass effect or spinal cord compression.
  4. Known hypersensitivity to any component of IP, including mRNA/LNP-based products.
  5. History of another primary malignancy within the past 3 years, except adequately treated basal cell carcinoma, squamous cell carcinoma, or cervical carcinoma in situ.
  6. Active hepatitis B (HBsAg-positive with detectable HBV DNA) or hepatitis C (HCV RNA-positive) infection.
  7. Active or prior HIV infection.
  8. Uncontrolled active systemic infection requiring IV therapy within 1 week before dosing.
  9. Active or history of acute/chronic GVHD.
  10. Inadequate hematologic function (ANC <1.0×10⁹/L, Hb <70 g/L, PLT <50×10⁹/L, lymphocytes ≤0.5×10⁹/L) or coagulation abnormalities (INR/APTT ≥1.5×ULN).
  11. Hepatic impairment (ALT/AST >2×ULN, or >3×ULN with hepatic involvement; bilirubin >2×ULN, unless Gilbert syndrome).
  12. Renal impairment (CrCl <50 mL/min by Cockcroft-Gault).
  13. Uncontrolled ischemic heart disease, NYHA Class III-IV heart failure, or baseline QTcF ≥450 ms (male) / ≥470 ms (female).
  14. Severe psychiatric disorder history.
  15. Pregnancy or breastfeeding.
  16. Received prohibited treatments within 4 weeks before dosing, including high-dose corticosteroids (>20 mg prednisone equivalent daily), chemotherapy, immunosuppressive therapy, prior CAR-T or other gene/cell therapy, or T-cell engagers.
  17. Participation in another clinical study with investigational therapy within 3 months before dosing, or prior participation in cell/gene therapy trials.
  18. Planned radiotherapy within 6 weeks after screening (unless only non-irradiated PET-positive lesions remain eligible).
  19. Planned allogeneic HSCT within 90 days after screening.
  20. Significant comorbidities or unstable medical conditions deemed by the investigator to compromise safety or study compliance.

引自 ClinicalTrials.gov, NCT07774572, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07774572,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07774572